药品:光化性角化病药物Picato存在致癌风险,EMA已取消授权( 二 )


2、EMA review of Picato concludes medicine’s risks outweigh its benefits
3、FDA Drug Safety Communication: FDA warns of severe adverse events with application of Picato (ingenol mebutate) gel for skin condition; requires label changes